SIRNAOMICS LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.97 HKD | +9.78% |
|
-2.02% | -79.72% |
| 05-10 | Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director | CI |
| 04-17 | Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,030 | 649.8 | 401.8 | 80.68 | - | - |
| Enterprise Value (EV) 1 | 818.3 | 573.7 | 401.8 | 80.68 | 80.68 | 80.68 |
| P/E ratio | -4.84 x | -6.38 x | -4.45 x | -0.66 x | - | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 40.3 x | 1.15 x | 0.5 x |
| EV / Revenue | - | - | - | 40.3 x | 1.15 x | 0.5 x |
| EV / EBITDA | -18.7 x | -7.39 x | -5.63 x | -0.59 x | - | - |
| EV / FCF | -15.1 x | -7.32 x | - | -0.67 x | -0.51 x | -0.58 x |
| FCF Yield | -6.63% | -13.7% | - | -149% | -197% | -171% |
| Price to Book | 4.87 x | 5.33 x | 9.99 x | -0.77 x | - | - |
| Nbr of stocks (in thousands) | 88,067 | 87,795 | 87,638 | 86,816 | - | - |
| Reference price 2 | 11.70 | 7.401 | 4.585 | 0.9293 | 0.9293 | 0.9293 |
| Announcement Date | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 2 | 70 | 161 |
| EBITDA 1 | -55.16 | -87.9 | -71.38 | -136 | - | - |
| EBIT 1 | -56.79 | -91.83 | -77.54 | -134 | -149 | -131 |
| Operating Margin | - | - | - | -6,700% | -212.86% | -81.37% |
| Earnings before Tax (EBT) 1 | -215.9 | -97.38 | -84.99 | -134 | - | - |
| Net income 1 | -213.1 | -88.3 | -78.69 | -124 | - | - |
| Net margin | - | - | - | -6,200% | - | - |
| EPS 2 | -2.419 | -1.160 | -1.030 | -1.410 | - | - |
| Free Cash Flow 1 | -68.33 | -88.74 | - | -120 | -159 | -138 |
| FCF margin | - | - | - | -6,000% | -227.14% | -85.71% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | 212 | 76.1 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -68.3 | -88.7 | - | -120 | -159 | -138 |
| ROE (net income / shareholders' equity) | - | -52.9% | -97% | - | - | - |
| ROA (Net income/ Total Assets) | - | -43.6% | -65.7% | -119% | - | - |
| Assets 1 | - | 202.3 | 119.9 | 104.6 | - | - |
| Book Value Per Share 2 | 2.400 | 1.390 | 0.4600 | -1.200 | - | - |
| Cash Flow per Share 2 | -3.820 | -1.170 | -0.9200 | -1.430 | - | - |
| Capex 1 | 11.4 | 18.8 | - | 5 | 5 | 5 |
| Capex / Sales | - | - | - | 250% | 7.14% | 3.11% |
| Announcement Date | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9293
USD
Average target price
9.231
USD
Spread / Average Target
+893.34%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -79.72% | 82.55M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- 2257 Stock
- Financials Sirnaomics Ltd.